A randomized study comparing topotecan plus cisplatin versus etoposide plus carboplatin for previously untreated small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 10, Issue 2, 2007, Pages 144-147

  Zhang, Shucai ^a   Wang, Jinghui ^a   Wang, Qunhui ^a   Zhang, Hui ^a   Hu, Fanbin ^a   Yang, Xinjie ^a   Fan, Xiaofang ^a   Wang, Haiyong ^a   Gu, Yanfei ^a   Li, Xi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Etoposide; First line; Small cell lung cancer; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THORAX SURGERY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 34247518688     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 49(2) : 119-133.
2. Greco FA. Topotecan as first-line therapy for small cell lung cancer. Lung cancer, 2003, 41 (Suppl 4) : S9-S16.
3. Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res, 2003, 9(1) : 143-150.
4. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 1996, 14(8) : 2345-2352.
5. Lilenbaum RC, Miller AA, Batist G, et al. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia-Group B study. J Clin Oncol, 1998, 16(10) : 3302-3309.
6. Seifart U, Jensen K, Ukena J, et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer, 2005, 48(3) : 415-422.
7. Quoix E, Breton JL, Gervais R, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer, 2005, 49 (2) : 253-261.
8. Stewart DJ. Topotecan in the first-line treatment of small cell lung cancer. Oncologist, 2004, 9 Suppl 6 : 33-42.
9. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol, 1994, 5(7) : 601-607.
10. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol, 2006, 24(13) : 2044-2051.
11. Sorensen M, Jensen PB, Herrstedt J, et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol, 2000, 11(7) : 829-835.
12. Fujiwara K, Ueoka H, Kiura K, et al. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemother Pharmacol, 2006, 57(6) : 755-760.